Molecular Partners: Pipeline Momentum and Early Safety Data Support Unchanged $12 Price Target and Buy RatingTip Ranks·Aug 25 at 03:15 PMMOLN-3.27%
MOLN: MP0712 advances in SCLC trials, CD70 program announced, and cash runway extends into late 2027Quartr·Aug 25 at 02:21 AMMOLN-3.27%
MOLN: Cash of CHF 68M supports advancing DARPin oncology pipeline, with key data expected in 2026Quartr·Aug 25 at 12:12 AMMOLN-3.27%
Molecular Partners H1 FY26 net loss narrows to CHF 26.7 million; operating loss improves to CHF 27 millionPUBT·Aug 25 at 12:00 AMMOLN-3.27%
Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study | MOLN Stock NewsStockTitan·Aug 24 at 04:00 PMMOLN-3.27%
Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Short Interest Down 49.3% in JulyMarket Beat·Aug 16 at 02:20 PMMOLN-3.27%
Molecular Partners doses first patients in Phase 2 MP0317 combo trial for cholangiocarcinomaPUBT·Jul 20 at 07:23 AMMOLN-3.27%
Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma | MOLN Stock NewsStockTitan·Jul 15 at 04:00 PMMOLN-3.27%
Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference | MOLN Stock NewsStockTitan·Jul 14 at 04:00 PMMOLN-3.27%
